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Introduction
The cellular environment is comprised of millions of proteins 
packed into their respective subcellular locales. Thus, the cell has 
a daunting task of maintaining proper protein homeostasis, or 
proteostasis, in the face of intrinsic and environmental stressors. 
More encompassing than protein quality control, proteostasis in-
volves the global regulation of transcription, translation, folding, 
trafficking, processing, assembly/disassembly, localization, and 
degradation (Fig. 1). Thus, the proteostasis concept entails an 
elaborate and integrated cellular network that governs the “life of 
proteins” from conception to their demise (Balch et al., 2008). 
Interplay between proteostasis network components is essential 
for the long-term health of the cell. Due to the complexity of the 
integrated network, defects in any one branch can elicit a break-
down of the entire network and manifest themselves in numerous 
metabolic, oncological, cardiovascular, and neurodegenerative 
diseases. Thus, a convergence of different biological and bio-
medical disciplines is critical to reach a thorough understanding 
of proteostasis in the context of disease.
Proteostasis network components play critical roles in gov-
erning the life of disease proteins. Numerous neurodegenerative 
diseases are characterized by the misfolding and accumulation of 
select proteins in insoluble inclusions or aggregates. Clinical   
onset does not typically occur until middle age or later depending 
on whether the disease state arises via familial or sporadic means. 
Thus, neurons can sustain conformationally challenged, disease 
proteins in benign states for decades until age-associated altera-
tions in cellular stasis predispose different neuronal populations 
to neurotoxicity.
Genetic and environmental factors responsible for numer-
ous neurodegenerative diseases vary between disorders, 
yet age remains a universal risk factor. Age-associated   
decline in protein homeostasis, or proteostasis, enables   
disease-linked proteins to adopt aberrant tertiary structures, 
accumulate as higher-ordered aggregates, and cause a 
myriad of cellular dysfunctions and neuronal death. How-
ever, recent findings suggest that the assembly of disease 
proteins into tightly ordered aggregates can significantly 
delay proteotoxic onset. Furthermore, manipulation of met-
abolic pathways through key signaling components extends 
lifespan, bolsters proteostasis networks, and delays the   
onset of proteotoxicity. Thus, understanding the relationship 
between proteostasis and aging has provided important 
insights into neurodegeneration.
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Figure 1.  Proteostasis landscape deteriorates with time. Integrated com-
ponents of the protein homeostasis network are arbitrarily represented as 
a global landscape. General activity for transcription, translation, folding, 
trafficking,  processing,  assembly/disassembly,  localization,  and  degra-
dation are depicted as nodes in which node amplitude signifies strength 
of homeostatic activity. Nodes are designated with the color indicated in 
the legend below and assigned an arbitrary value for activity. Proteomic 
breakdown resultant from age can be attributed to a general deterioration 
in each proteostasis hub.
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partners for other -sheet–rich proteins and enable polypeptides 
to  pack  tightly  into  fibrous  protein  structures  (Caughey  and 
Lansbury, 2003; Nelson et al., 2005). Many of the amyloid dis-
eases possess a toxic gain-of-function because their aberrant ter-
tiary and quaternary structures trigger pathogenic cascades as 
opposed to loss-of-function diseases in which removal of essen-
tial proteins via misfolding or premature degradation is at the 
root of pathogenesis. Gain-of-function diseases have been quite 
perplexing due to the multitude of dysfunctional outputs that   
include, but are not limited to, transcriptional deregulation, 
oxidative and membrane damage, mitochondrial injury, aberrant 
trafficking and signaling, neuroinflammation, and disrupted ion 
homeostasis (Bossy-Wetzel et al., 2004; Fiala, 2007).
For decades, amyloid deposits formed by disease-linked 
proteins were considered to be the toxic species due to their over-
whelming presence in the brains of postmortem patients. Yet   
a poor correlation exists between the degree of amyloid accumu-
lation and the clinical severity of the different disease states.   
In fact, multiple proteins are capable of forming benign amyloid 
structures that function in phenotypic adaptation in Saccharo­
myces cerevisiae (True et al., 2004; Shorter and Lindquist, 2005) 
and melanin synthesis in humans (Fowler et al., 2006). These 
observations prompted researchers to reexamine amyloid assem-
bly pathways in disease. Recent work has begun to challenge the 
notion that amyloid is indeed the underlying toxic species in 
conformational diseases and may rather represent a protective 
mechanism used by cells to ameliorate soluble, toxic intermedi-
ates in the amyloid assembly pathway (Fig. 3; Behrends et al., 
2006; Cohen et al., 2006; Douglas et al., 2008). Interestingly, the 
amyloidogenic intermediates formed by multiple disease pro-
teins share similar structures due to recognition by a single 
Proteostasis declines as a function of time and may pro-
vide a feasible explanation as to why age is a major risk factor 
for such neurodegenerative diseases (Balch et al., 2008). Molec-
ular chaperones and degradation machinery normally act as a 
first line of defense to solubilize, refold, or degrade misfolded 
proteins, yet age compromises these protein quality control com-
ponents (Sherman and Goldberg, 2001; Morimoto, 2008). Thus, 
aged cells show an increasing inability to maintain metastable 
proteins in properly folded states (Ben-Zvi et al., 2009). Further-
more, a specific mechanism in the brains of aged individuals 
causes frame shift mutations at the RNA level and generates 
nonsense polypeptides, which further burdens the proteome (van 
Leeuwen et al., 1998). The introduction of metastable, disease-
linked proteins can escape protein quality control later in life and 
initiate a cascade of protein destabilization in the face of deterio-
rating proteostasis networks (Gidalevitz et al., 2006). Due to the 
global breakdown of proteostasis with age, cells must manage 
the increasing burden of protein misfolding without a means of 
efficiently controlling protein synthesis, processing, localization, 
refolding, or degradation pathways.
Aging was initially thought to be a random process of dete-
rioration that occurred independent of genetic control (Reichel, 
1966). However, evidence for the genetic modulation of aging 
across the evolutionary scale has silenced old dogma and opened 
up an era with limitless possibilities for improved health and dis-
ease intervention (Kenyon, 2010). Central to the concept of age 
modulation are the cellular and organismal responses to environ-
mental conditions such as nutrient availability and stress (Fig. 2). 
Indeed, manipulation of stress response genes and nutrient sen-
sors extends lifespan. Moderate reduction in caloric intake trig-
gers  alterations  in  cellular  physiology  and  mediates  lifespan 
extension and increased resistance to stress (Bishop and Guarente, 
2007). The cellular response to dietary restriction is complex   
and, depending on the food regimen (Mair et al., 2009), requires 
different signaling pathways including nutrient sensors such as 
the kinase target of rapamycin (TOR; Kapahi et al., 2004;   
Kaeberlein et al., 2005b), AMP kinase (Greer et al., 2007), sirtu-
ins (Rogina and Helfand, 2004) and insulin/insulin-like growth 
factor (IGF-1; Arum et al., 2009; Honjoh et al., 2009) as well   
as stress response genes such as heat-shock factor 1 (HSF-1; 
Steinkraus et al., 2008) and hypoxia-inducible factor (HIF-1; 
Chen et al., 2009). We highlight how different age-extension 
components modulate proteostasis networks in a manner which 
protects against proteotoxicity and neurodegeneration.
Proteotoxicity and neurodegeneration
The misfolding and accumulation of disease proteins character-
izes numerous late-onset neurodegenerative diseases including 
Alzheimer’s, Huntington’s, and Parkinson’s disease. Pathogenic 
states resulting from protein destabilization and inclusion forma-
tion are often referred to as conformational diseases. The par-
ticular disease protein defines the disorder and can vary in 
functionality between different diseases, yet pathogenesis may 
occur by a common mechanism due to the formation of similar 
amyloid-like inclusions (Carrell and Lomas, 1997). Amyloids 
are highly ordered, fibrillar aggregates in which exposed -sheets 
from aberrantly folded proteins serve as hydrogen bonding   
Figure 2.  Environment influences neurodegeneration through age modi-
fiers and proteostasis networks. Environmental cues such as food avail-
ability or extrinsic stress alter age-modifying, signaling pathways such as 
insulin/IGF-1, target of rapamycin (TOR), sirtuins, heat shock factor (HSF), 
and hypoxia-inducible factor (HIF-1). Elaborate interplay between the dif-
ferent signaling pathways modulates proteostasis and impacts onset and 
progression of numerous neurodegenerative diseases.721 Protein homeostasis and aging in neurodegeneration • Douglas and Dillin
Insoluble fibrillar deposits formed by the Tau protein rep-
resent the other major pathogenic marker for Alzheimer’s dis-
ease as well as other diseases characterized by Tau fibrils (termed 
tauopathies). These neurofibrillary tangles are typically observed 
within the cell bodies and dendrites of neurons (Kidd, 1963). 
Particularly enriched in neurons (Binder et al., 1985), Tau acts as 
a microtubule-stabilizing protein (Drechsel et al., 1992) that is 
normally phosphorylated at multiple sites. Yet abnormal hyper-
phosphorylation of Tau reduces its microtubule binding capacity 
(Alonso et al., 1994) and accelerates aggregation (Alonso et al., 
1996). Thus, disruptions in proteostasis networks resultant from 
age may increase kinase or decrease phosphatase activity, al-
though further investigation is required. Furthermore, other post-
translational modifications of Tau may play important roles in 
regulating its phosphorylation and aggregation status such as   
O-GlcNAcylation, ubiquitination, sumoylation, and nitration 
(Liu et al., 2004; Gong et al., 2005).
Neurofibrillary tangles were previously implicated as the 
key Tau component in Alzheimer’s pathogenesis (Arriagada   
et al., 1992; Bennett et al., 2004). Yet recent studies demonstrate 
that the formation of neurofibrillary tangles can be uncoupled 
from  cognitive  decline  and  neuronal  death  (Santacruz  et  al., 
2005). Thus, neurofibrillary tangles may not represent the toxic 
Tau species, at least in the early stages of pathogenesis. In fact, 
oligomeric intermediates in the Tau aggregation pathway more 
closely correlate with the development of functional deficits dur-
ing disease progression (Berger et al., 2007). In cases of Tau and 
A, it appears that intermediates in the amyloid assembly path-
way represent the toxic culprit. However, it remains controver-
sial whether A or Tau is the predominant component behind 
neuronal dysfunction and death in Alzheimer’s disease.
Polyglutamine expansion diseases. CAG nucleo-
tide expansions within a set of unrelated genes are the cause of 
at least nine different late-onset neurodegenerative diseases, 
which include Huntington’s disease, spinobulbar muscular atro-
phy, and the spinocerebellar ataxias (Ross, 2002). Huntington’s 
disease represents the most widely studied of these disorders and 
is classified as a hyperkinetic movement disorder. The disease 
state arises due to glutamine-encoding expansions in the hun-
tingtin gene, usually beyond a critical threshold of 40 glutamine 
residues (Zoghbi and Orr, 2000), which results in the accumula-
tion of mutant huntingtin protein within intranuclear inclusion 
bodies (DiFiglia et al., 1997). However, pathogenesis does not 
correlate well with the concentration and subcellular distribution 
of huntingtin inclusions (Saudou et al., 1998; Kuemmerle et al., 
1999). In fact, inclusion body formation by mutant huntingtin 
sequesters soluble forms of the mutant protein and reduces cell 
death in cultured neurons (Arrasate et al., 2004). Furthermore, 
inclusion body formation of mutant huntingtin by pharmacologi-
cal means ameliorates proteosomal dysfunction, a common fea-
ture in huntingtin-induced proteotoxicity (Bodner et al., 2006). 
These data suggest a mechanism for neurotoxicity that likely in-
volves soluble, oligomeric forms of mutant huntingtin rather 
than higher-ordered inclusions. Indeed, the intracellular accu-
mulation of low-molecular weight oligomers formed by poly-
glutamine expansions correlated with toxicity in cell culture and 
yeast (Kitamura et al., 2006). Elevated expression of a potent 
antibody and further bolster the notion for a common mecha-
nism of pathogenesis (Kayed et al., 2003). Thus, a common 
means for therapeutic intervention may transcend multiple con-
formational diseases. These paradigm-shifting results have led 
the field to revise previously held notions of amyloid formation 
and its role in neurodegeneration.
Alzheimer’s  disease.  Over  a  century  ago,  fibrillar 
structures were discovered within the brains of postmortem pa-
tients exhibiting progressive cognitive dysfunction and psycho-
sis by Alois Alzheimer (Alzheimer et al., 1995). Since then, 
Alzheimer’s disease has become the most widely studied neuro-
degenerative disorder. Numerous heritable mutations in the   
amyloid precursor protein (APP) have been linked to disease 
onset during the fifth decade of life, whereas a majority of the   
Alzheimer’s cases are sporadic and develop clinical onset dur-
ing the seventh decade or later. The disease state arises due to 
sequential cleavage of APP (Glenner and Wong, 1984) by the   
-secretase, -site APP-cleaving enzyme or BACE1 (Farzan et al., 
2000), followed by presenilin-1, a component of the -secretase 
complex (Wolfe et al., 1999). These endoproteolysis events gen-
erate A peptides comprised of 40- and 42-amino acid residues, 
A40 and A42, which subsequently assemble into extracellular 
amyloid  plaques  (Selkoe,  2004). Autosomal  dominant  muta-
tions in APP and the presenilins, PS1 and PS2, are responsible 
for familial forms of Alzheimer’s disease and subsequently 
lead to increased production of the amyloidogenic A42 rela-
tive to A40 (Sisodia and St George-Hyslop, 2002). Addition-
ally, patients with APP gene duplications or individuals with 
Down’s syndrome (trisomy 21), who have increased dosage of 
the APP gene located on chromosome 21, develop early-onset 
Alzheimer’s disease and overproduce A42 (Hardy, 2006).   
Alternatively, -secretase cleaves APP within the A domain 
and ameliorates A formation (Weidemann et al., 1989; Esch 
et al., 1990). In fact, -secretase processing of APP generates 
a soluble ectodomain termed APPs, which may possess neuro-
protective properties (Postina, 2008). Thus, the proteolytic gen-
eration and cellular management of A42 play a central role in 
Alzheimer’s pathogenesis.
Recent findings have begun to challenge the notion that A 
plaques are the primary neurotoxic species in Alzheimer’s dis-
ease but may rather represent the proteinaceous aftermath of   
neuronal dysfunction or a protective depot for A aggregation 
intermediates. Transgenic mouse models have shown that intra-
cellular A initiates neuronal dysfunction before it accumulates 
in extracellular plaques (Chui et al., 1999; Hsia et al., 1999;   
Kumar-Singh et al., 2000). Refocused efforts have demonstrated 
that  soluble,  oligomeric  intermediates  in  the A  aggregation 
pathway are the most toxic entity (Haass and Selkoe, 2007; 
Shankar et al., 2008). In fact, driving active assembly of A into 
amyloid  fibrils  reduces  the  concentration  of  intermediate A 
oligomers and functional deficits in tissue culture (Cheng et al., 
2007), Caenorhabditis elegans (Cohen et al., 2006), and mouse 
models (Cohen et al., 2009). Finally, transgenic mice express-
ing a mutant form of A that enables oligomerization without   
fibrillization are equally susceptible to Alzheimer’s disease–like   
syndromes  as  animals  expressing A  that  can  form  amyloid 
(Tomiyama et al., 2010).JCB • VOLUME 190 • NUMBER 5 • 2010   722
2000; van der Putten et al., 2000; Lo Bianco et al., 2002).   
Subsequent overexpression of -synuclein in cell culture led to 
cytotoxicity in the presence of dopamine (Moussa et al., 2004). 
These  observations  have  linked  -synuclein  dysfunction  with 
Parkinson’s disease pathogenesis. Yet the identity of the cytotoxic 
species formed by -synuclein remained unclear. Driving large 
inclusions of -synuclein by pharmacological means protected 
against cytotoxicity (Bodner et al., 2006). A major catechin 
of green tea, ()-epigallocatechin-3-gallate (EGCG), converted 
large -synuclein inclusions into smaller, amorphous protein   
aggregates that were not toxic to mammalian cells. The mode of   
action reveals that the compound directly binds to -sheet–rich 
-synuclein aggregates and mediates their conformational change 
without their disassembly into small diffusible oligomers (Bieschke 
et al., 2010). Thus, soluble oligomers formed by -synuclein 
most likely represent the toxic proteinaceous species and the for-
mation of higher-ordered aggregates, whose nature is still being 
defined, can reduce the proteotoxic load.
Prion  diseases. The infectious protein phenomena   
underlies multiple transmissible spongiform encephalopathies 
which include scrapie in sheep and goats, bovine spongiform 
encephalopathy or mad cow disease, chronic wasting disease in 
deer and elk, and Creutzfeldt-Jakob disease in humans. Central 
to prion diseases is the conversion of the prion protein, PrP
C, into 
the infectious, -sheet–rich isoform, PrP
SC, which drives the auto-
catalytic conversion of normal PrP
C into the pathogenic PrP
SC 
and enables its accumulation in amyloid aggregates (Prusiner, 
1998).  PrP
C  is  a  nonessential  glycosylphosphatidylinositol- 
anchored glycoprotein of unknown function that is ubiquitously 
expressed throughout the brain. Interestingly, PrP
C expression is 
required for neurotoxicity and prion replication as mice devoid 
of PrP
C are resistant to infection and disease (Büeler et al., 1993). 
Multiple models have been proposed for the underlying causes 
of prion pathogenesis, yet it is still not clear whether neuro-
degeneration is due to a loss of functional PrP
C or a toxic gain- 
of-function by PrP
SC. Consistent with other neurodegenerative 
diseases, clinical symptoms can manifest without any obvious 
scrapie deposits (Collinge et al., 1990; Medori et al., 1992). 
Rather, soluble oligomers formed by PrP possess higher degrees 
of infectivity (Silveira et al., 2005) and neurotoxicity (Kazlauskaite 
et al., 2005; Simoneau et al., 2007) than the higher-ordered amy-
loid fibrils. Thus, prion diseases adhere to the common trend 
whereby soluble oligomers formed by disease-linked proteins 
represent the most toxic entity. Amyloid deposition may reduce 
oligomeric concentration and delay proteotoxic onset.
Genetic modifiers of age protect  
against neurodegeneration
Proteostasis networks buffer the constant flux of protein misfold-
ing caused by the inherently error-prone nature of protein synthe-
sis and degradation. Yet proteostasis networks deteriorate as a 
function of time and make cells more vulnerable to proteotoxic 
stress. Genetic mutations within conformational disease proteins 
and environmental stress can further increase the burden of de-
stabilized proteins and cause irreversible damage to aged cells. 
However, manipulating the aging process through key metabolic 
signaling molecules can hamper age-mediated proteostasis 
suppressor of polyglutamine toxicity, the TriC chaperonin com-
plex (Nollen et al., 2004), remodeled 200-kD proteotoxic oligo-
mers into benign 500-kD aggregates in a yeast model (Behrends 
et al., 2006). These data provided some of the first examples by 
which depletion of toxic oligomers through protective aggrega-
tion correlates with disease protein detoxification.
Parkinson’s disease. Parkinson’s disease is the second 
most common age-related neurodegenerative disease. The dis-
ease is characterized by the accumulation of -synuclein, a 
presynaptic protein of unknown function, in Lewy bodies that 
particularly affect the dopaminergic neurons in the substantia 
nigra (Dauer and Przedborski, 2003). The majority of Parkinson’s 
disease cases are sporadic, yet mutations have been identified   
in familial cases of the disease. Single point mutations in the   
-synuclein protein (A30P, A53T, and E46K) have been identified 
in early-onset Parkinson’s disease patients (Lotharius and Brundin, 
2002; Moore et al., 2005). Additionally, triplication of the   
-synuclein gene causes Parkinson’s disease in some individuals 
(Singleton et al., 2003). Elevated expression of the human   
-synuclein led to dopaminergic neuronal degeneration and motor 
deficits in transgenic fly, mice, and rat models (Feany and Bender, 
Figure 3.  Aging modifiers intervene in the life of disease proteins. The 
model depicts synthesis, folding, processing, degradation, and aggrega-
tion of an arbitrary disease-linked protein. Age modifiers including TOR, 
sirtuins, and insulin/IGF-1 act at multiple points within the protein aggre-
gation cascade to ameliorate the accumulation of proteotoxic intermedi-
ates. The corresponding letters A–L are briefly described and referenced 
in Table I.723 Protein homeostasis and aging in neurodegeneration • Douglas and Dillin
amyloidogenic A-peptides) in a nematode model (Steinkraus   
et al., 2008). Human studies indicate that increased caloric in-
take may accelerate Alzheimer’s disease pathogenesis (Hendrie 
et al., 2001; Luchsinger et al., 2002). Subsequent analysis of   
Alzheimer’s disease models in mice revealed that restricted food 
regimens prevented the generation of A peptides and plaque de-
position in mouse brains through increases in anti-amyloidogenic 
-secretase activity (Wang et al., 2005). Similarly, reductions   
of calorie intake in squirrel monkeys showed a dramatic de-
crease in the steady-state levels of amyloidogenic A, which 
correlated with increased -secretase levels but not the A pep-
tide generating - and -secretases (Qin et al., 2006a). Dietary 
restriction in adult mice also increases resistance of striatal   
dopaminergic neurons to the neurotoxin MPTP (1-methyl-4- 
phenyl-1,2,3,6-tetrahydropyridine) in a Parkinson’s disease 
model (Duan and Mattson, 1999). Thus, dietary restriction at-
tenuates the deleterious effects of neurodegeneration in multiple 
disease models.
Recent research has begun to identify key molecular com-
ponents required for dietary restriction–mediated protection 
against disease protein misfolding and aggregation. Although 
dietary restriction has been well established as an age-extension 
phenomena, relatively little is known regarding the mechanism 
of action. Genetic analyses have linked multiple age-extension 
components including the kinase TOR, AMP kinase, HSF-1, 
HIF-1, sirtuins, and insulin/IGF-1 signaling to dietary restric-
tion. However, these results seem somewhat variable and occa-
sionally  opposing.  Inconsistencies  between  different  research 
groups may be attributed to the complexity of the dietary restric-
tion response and method by which dietary restriction is admin-
istered in the different model organisms (Mair et al., 2009). 
collapse and significantly delay the onset of neurodegeneration 
caused by conformationally challenged, disease proteins. These 
age-extension components act at multiple stages in the misfolding 
and aggregation pathway to inhibit transcription or translation, 
reduce aberrant processing, and promote disease protein refold-
ing, degradation, or active aggregation (Fig. 3 and Table I).
Dietary  restriction. Caloric or dietary restriction 
represents one of the most studied phenomena known to extend 
lifespan. Organisms ranging from single-cell eukaryotes to 
mammals balance growth and reproduction with environmental 
stress and nutrient availability. Under optimal conditions with 
ample food, organisms allocate energy expenditure in favor of 
growth, development, and reproduction. Yet challenging condi-
tions or limited food availability elicit global physiological re-
sponses that divert energy into protective pathways, assist in 
proper cellular stasis, and can also extend lifespan. Moderate 
decrease in calorie intake without malnutrition extends lifespan 
in yeast, flies, worms, mice, and primates (Colman et al., 2009). 
Dietary restriction has also been shown in multiple disease 
models to attenuate proteotoxicity caused by different confor-
mational disease proteins.
Dietary  restriction  can  significantly  delay  the  develop-
ment of spontaneous age-related changes in the brain (Finch and 
Cohen, 1997). For instance, dietary restriction suppresses age- 
related decreases in synaptic spine density in the neocortex of rats 
(Moroi-Fetters et al., 1989) and significantly reduces the age- 
related degeneration of spiral ganglion auditory neurons in mice 
(Park et al., 1990). The protective aspects of dietary restriction 
on cellular health extend to different disease models. Dietary   
restriction delays the proteotoxic onset caused by different con-
formational disease proteins (polyglutamine expansions and 
Table I. Age modifiers and neurodegeneration
Disease Protein Disease Age modifier Organism Reference
A PrP Prion diseases SIRT1 knockout Mouse Chen et al., 2008
B -Synuclein Parkinson’s disease Rapamycin inhibition  
of TOR and 4E-BP  
overexpression
Drosophila Tain et al., 2009
C Polyglutamine expansion,  
Tau
Polyglutamine-expansion  
diseases, Alzheimer’s  
disease
Rapamycin inhibition  
of TOR
Tissue culture and 
Drosophila
Berger et al., 2006
D Polyglutamine expansion Polyglutamine-expansion  
diseases
Rapamycin inhibition  
of TOR
Tissue culture,  
Drosophila, 
mice, and  
human
Ravikumar et al., 2004
E A Alzheimer’s disease Resveratrol activation  
of Sirtuin
Cell culture Marambaud et al., 2005
F — — Deletion and overexpres-
sion of SIRT1
Mouse Lee et al., 2008
G A Alzheimer’s disease SIRT1 overexpression Mouse Qin et al., 2006b
H -Synuclein Parkinson’s disease SIRT2 inhibition Cultured neurons  
and Drosophila
Outeiro et al., 2007
I A Alzheimer’s disease IRS-2, neuronal IGF-1R  
and insulin receptor 
knockout
Mouse Freude et al., 2009
J A Alzheimer’s disease IGF-1 overexpression Mouse Palazzolo et al., 2009
K A Alzheimer’s disease DAF-2 reduction C. elegans Cohen et al., 2006
L A Alzheimer’s disease IGF-1R reduction Mouse Cohen et al., 2009
References and descriptions for Fig. 3. Each letter highlights its respective arrow in Fig. 3 and references the corresponding study.JCB • VOLUME 190 • NUMBER 5 • 2010   724
in transgenic worms, yet its effect on proteotoxicity and lifespan 
were not examined in this study (van Ham et al., 2008). Resver-
atrol also antagonized degeneration of cultured neurons caused 
by the neurotoxin 1-methyl-4-phenylpyridinium (MPP), which 
selectively targets dopaminergic neurons and is a widely used 
agent to mimic Parkinson’s disease in rodents (Alvira et al., 
2007). In contrast, flies appear to show opposing effects whereby 
reductions in the dSir2 activity by genetic and pharmacological 
means promoted neuronal survival in mutant huntingtin trans-
genic flies (Pallos et al., 2008). Similarly, SIRT1 knockout mice 
exhibited delayed onset of prion disease (Chen et al., 2008). 
Thus, activation and inhibition of Sir2 orthologues drastically 
affects proteotoxicity. However, these effects are dependent on 
the disease protein and model organism.
The ability of Sir2 orthologues to modulate lifespan and 
proteotoxicity prompted researchers to examine the mechanistic 
links of SIRT1’s role in age and proteome maintenance. Activa-
tion of SIRT1 positively regulates the heat-shock factor, HSF-1 
(Westerheide et al., 2009). HSF-1 extends lifespan in worms 
(Hsu et al., 2003; Morley and Morimoto, 2004) and regulates the 
expression of numerous molecular chaperones that are potent 
modulators  of  protein  aggregation  and  neurodegeneration 
(Muchowski and Wacker, 2005; Douglas et al., 2009). Thus, the 
ability of SIRT1 to maintain proteome stability and protect 
against proteotoxicity may act, at least in part, through the acti-
vation of the stress response gene HSF-1.
The ability of sirtuins to modulate proteostasis enables it to 
intervene at multiple stages in the disease protein aggregation 
pathway and delay proteotoxic onset. It can act early in the disease 
protein aggregation pathway to ameliorate flux of disease proteins 
through the cell. SIRT1 knockout as well as dietary restriction in a 
mouse model reduced PrP mRNA and protein levels, which corre-
lated with delayed prion disease onset (Fig. 3 A; Chen et al., 2008). 
Additionally, dietary restriction exerted no further protection on 
SIRT1 knockout mice, which further suggests that the dietary re-
striction cascade acts through SIRT1. We previously discussed 
that dietary restriction can promote the anti-amyloidogenic activ-
ity of -secretase in Alzheimer’s disease models and reduce the 
production of pathogenic A. In a similar manner, elevated ex-
pression of SIRT1 in mammalian neurons prevented A produc-
tion via altered cleavage of APP by -secretase (Fig. 3 G; Qin   
et al., 2006b). It remains unclear why removal or overexpression of 
the same sirtuin isoform, SIRT1, can intervene at different point in 
the disease protein aggregation pathway and protect against pro-
teotoxicity. The most likely explanation involves distinct roles for 
SIRT1 in Alzheimer’s and prion disease. However, further study is 
required to better address this conundrum. Nonetheless, modulat-
ing Sir2 orthologue levels can decrease synthesis and aberrant 
processing of different disease proteins and ultimately reduce pro-
teotoxic flux through the cell.
Sirtuins can also act later in the aggregation cascade to 
promote removal of toxic oligomeric intermediates formed by 
disease-linked proteins. As sirtuins can promote favorable pro-
cessing pathways for APP, they can also promote degradation of 
the amyloidogenic A peptide potentially through both major 
branches of the protein degradation network. Activation of sirtu-
ins by resveratrol reduced A levels by promoting degradation 
Regardless, age-extension components, which may or may not 
regulate dietary restriction–induced longevity, intervene at mul-
tiple steps in the disease protein misfolding and aggregation 
pathway to delay the onset of proteotoxicity.
Sirtuin. The sirtuin family of deacetylases has become 
one of the widest studied components in aging and age-related 
diseases. The identification of multiple pharmacological activa-
tors of sirtuins, including the widely studied resveratrol, has   
accelerated our understanding of sirtuin’s role in aging and neuro-
degeneration. The high conservation of sirtuins across the evolu-
tionary scale has also enabled researchers to pool knowledge from 
multiple model organisms. Yet diversity in the subcellular local-
ization and function of different sirtuin isoforms has made it diffi-
cult to discern their individual contributions in a vast array of 
cellular processes. Sirtuins were initially identified in yeast as si-
lent information regulators (SIRs; Rine and Herskowitz, 1987) 
that mediate deacetylation of both histone and nonhistone targets. 
Mammals possess seven sirtuin paralogues with SIRT1 being the 
closest to the yeast Sir2 (Haigis and Guarente, 2006). The role of 
sirtuins in aging was first discovered in S. cerevisiae as depletion 
of Sir2 shortened replicative lifespan, whereas overexpression 
lengthened replicative lifespan (Kaeberlein et al., 1999).
Sirtuins have since been linked to longevity mediated by 
dietary restriction. Increased replicative lifespan caused by re-
duction in glucose availability depends on the presence of the 
SIR2 gene in yeast (Lin et al., 2000). Yet the involvement of sir-
tuins in longevity mediated by dietary restriction remains con-
troversial. Replicative lifespan extension induced by glucose 
reduction is independent of Sir2 activity under certain conditions 
(Kaeberlein et al., 2004, 2005a). Consistent with the complexity 
of the dietary restriction response, the role of sirtuins in mediat-
ing age extension appears variable and depends on the specific 
dietary restriction conditions. In C. elegans, sir-2.1–mediated 
lifespan extension is dependent on the FOXO transcription fac-
tor DAF-16 (Tissenbaum and Guarente, 2001) and interactions 
with the 14-3-3 proteins (Berdichevsky et al., 2006). However, 
discerning the role of sirtuins in lifespan extension has yielded 
conflicting results. In one study, resveratrol treatments extended 
worm and fly lifespan in a Sir2 orthologue–dependent manner 
(Wood et al., 2004). Alternatively, resveratrol treatment had no 
effect on fly lifespan and variable results on worm lifespan (Bass 
et al., 2007). In a mouse model, resveratrol lengthened the life-
span of mice fed a high calorie diet (Baur et al., 2006) but had no 
effect on the lifespan of mice fed a standard diet (Pearson et al., 
2008). Despite conflicting findings regarding pharmacological 
analysis, the ability of Sir2 orthologues to promote longevity ex-
tends  across  the  evolutionary  scale,  yet  it  remains  unclear 
whether age extension through dietary restriction requires the 
activity of sirtuins.
Sirtuin’s beneficial role in the aging process has made it   
an attractive target in age-related neurodegenerative diseases.   
Resveratrol  protected  C.  elegans  and  mouse  neurons  against   
mutant huntingtin-induced cytotoxicity (Parker et al., 2005).   
Additionally, increased sir-2.1 gene dosage in the worm model   
of Huntington’s disease also protected against neurotoxicity 
in  a DAF-16–dependent manner. Subsequently, depletion of   
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of IGF-1 in culture reduced aggregation of the androgen receptor 
(AR), a polyglutamine-expanded protein underlying spinal and 
bulbar muscular atrophy (SBMA), and increased AR proteosomal 
clearance through phosphorylation of AR by the PI3K/AKT path-
way (Fig. 3 J; Palazzolo et al., 2009). Interestingly, SBMA is a 
neurodegenerative disease yet overexpression of IGF-1 in skeletal 
muscle rescued behavior and aberrant histopathology. Alterna-
tively,  reductions  in  insulin/IGF-1  signaling  can  promote  the   
ordered assembly of A peptides into amyloid aggregates. In a   
C. elegans model, knockdown of daf­2 expression delayed nema-
tode paralysis caused by ectopic expression of the A peptide and 
promoted A aggregation, which correlated with decreased con-
centrations of low-molecular weight A oligomers (Fig. 3 K;   
Cohen et al., 2006). This phenomenon was extended into mouse 
models of Alzheimer’s disease. Alzheimer’s mice heterozygous 
for the IGF-1 receptor exhibited reductions in insulin/IGF-1 signal-
ing and delayed the onset of disease symptoms including behav-
ioral impairment, neuroinflammation, and neuronal loss (Fig. 3 L;   
Cohen et al., 2009). Histopathological analysis of mice revealed 
that reductions in IGF-1 gene dosage promoted the formation of 
densely packed A aggregates, which resulted in decreased 
steady-state levels of the soluble A oligomers. These observa-
tions have provided compelling evidence for the protective effects 
of amyloid formation as a means of ameliorating the cellular con-
centration of neurotoxic oligomers. Indeed, disease protein aggre-
gates are space-filling lesions that may affect later stages of disease 
pathogenesis. Thus, cells may use aggregation pathways as a sec-
ondary means of disease protein detoxification when primary 
methods of solubilization and degradation have become compro-
mised as a result of increasing age and proteostasis collapse.
TOR  signaling. The TOR signaling pathway has been 
the most consistently linked to dietary restriction (Kenyon, 2010). 
The TOR kinase monitors intra- and extracellular availability of 
amino acids and nutrients. In the presence of ample food, TOR 
stimulates growth and inhibits salvage pathways such as autoph-
agy (Noda and Ohsumi, 1998). Inhibition of the TOR signal trans-
duction pathway by reduced nutrient availability or rapamycin 
treatment increases resistance to environmental stress (Hansen   
et al., 2007) and extends the lifespan of yeast (Kaeberlein et al., 
2005b), worms (Vellai et al., 2003), flies (Kapahi et al., 2004), 
and mice (Harrison et al., 2009). Unlike other lifespan extension 
pathways, TOR signaling does not require the activity of FOXO 
transcription factor DAF-16, but rather acts through the FOXA 
transcription factor PHA-4 in worms, which also mediates di-
etary restriction–induced lifespan extension in worms (Panowski 
et al., 2007). Consistent with the physiological shift toward tissue 
maintenance during nutrient deprivation, inhibition of TOR sig-
naling suppresses translation by inhibiting the ribosomal subunit 
S6 (Ma and Blenis, 2009) and activating 4E-BP, a translation re-
pressor (Brunn et al., 1997). Manipulation of translational regula-
tors downstream of TOR such as 4E-BP, S6 kinase, and translation 
initiation factors (eIF) modulates lifespan across the evolutionary 
scale (Evans et al., 2010). Furthermore, physiological changes 
resultant from TOR signaling inhibition can also protect against 
proteotoxic stress caused by disease protein aggregation.
Reductions in TOR signaling influence early events in the 
aggregation cascade by reducing the flux of disease proteins 
of A via the proteasome system (Fig. 3 E; Marambaud et al., 
2005). SIRT1 also deacetylates autophagy genes and stimulates 
basal autophagy (Fig. 3 F; Lee et al., 2008), which may play a 
role in clearance of A and other conformationally challenged 
proteins. Pharmacological inhibition of SIRT2 drove the forma-
tion of large and less toxic -synuclein aggregates in the cellular 
model for Parkinson disease and reduced neuronal deficits in 
culture and in a Drosophila model of Parkinson’s disease (Fig. 3 H; 
Outeiro et al., 2007). Thus, it has become apparent that different 
sirtuin members have very distinct roles in protein detoxification 
and it is not entirely clear how activation of SIRT1 and inhibition 
of SIRT2 both ameliorate proteotoxicity caused by disease pro-
tein aggregation. Differences in substrate recognition and sub-
cellular localization between the two sirtuin isoforms provide 
vague yet plausible explanations to this question and will require 
more intensive investigation to elucidate the molecular mecha-
nisms underlying these observations.
Insulin  signaling. The insulin/IGF signaling pathway 
regulates stress resistance and the aging process. Reductions in 
insulin/IGF signaling yield stress-resistant, long lived worms 
(Kenyon et al., 1993), flies (Tatar et al., 2001), and mice (Blüher 
et al., 2003; Holzenberger et al., 2003). The signal transduction 
pathway has been well characterized in the nematode C. elegans. 
The homologue of insulin/IGF-1 receptor, DAF-2, is a tyro-
sine kinase that binds to an insulin-like molecule, activates a 
phosphatidylinositol-3 kinase, AGE-1, and ultimately results in 
the phosphorylation and down-regulation of the FOXO tran-
scription factor, DAF-16 (Rincon et al., 2004). Manipulating 
any aspect of the insulin/IGF-1 cascade can result in stress- 
resistant, long-lived worms. The insulin/IGF-1 signaling pathway 
also plays a major role in the detoxification of model disease 
proteins as reduced signaling enables worms and mice to sustain 
proteotoxic insult caused by polyglutamine-expansions (Morley 
et  al.,  2002)  and  amyloidogenic A-peptides  (Cohen  et  al., 
2006, 2009). Insulin/IGF-1 signaling accomplishes disease pro-
tein detoxification by intervening at multiple points within the 
aggregation cascade.
Reductions in insulin/IGF-1 signaling act early in the dis-
ease protein aggregation pathway to protect against proteotoxicity.   
In a C. elegans model for polyglutamine expansion disease,   
reduced insulin/IGF-1 signaling by mutations within age­1 
(PI3K)  significantly  delayed  polyglutamine  aggregation  and 
proteotoxicity (Morley et al., 2002). Protection by reduced insulin/
IGF-1 was dependent on DAF-16. Yet it remains unclear whether 
reduced insulin/IGF-1 signaling acts at the level of protein syn-
thesis or maintenance of polyglutamine solubility. In a mouse 
model of Alzheimer’s disease, deficiencies in IRS-2, neuronal 
IGF-1R, or neuronal insulin receptor delayed mortality and de-
creased A accumulation by reduced amyloidogenic processing 
of APP (Fig. 3 I; Freude et al., 2009). Furthermore, IRS-2 null 
mice exhibited reductions in A accumulation and behavioral 
deficits (Killick et al., 2009). Thus, reduced insulin/IGF-1 sig-
naling can act at the level of protein processing to delay the pro-
duction of toxic proteinaceous species.
Other studies have implicated insulin/IGF-1 signaling as 
acting later in the disease protein aggregation pathway to reduce 
the cellular concentration of toxic oligomers. Elevated expression JCB • VOLUME 190 • NUMBER 5 • 2010   726
lifespan in worms and suppress proteotoxicity (Chen et al., 2009; 
Mehta et al., 2009), yet its mechanism of action in the disease-
protein aggregation cascade has not yet been defined. Through 
the earlier part of life, cells antagonize disease protein aggrega-
tion by reducing disease protein flux via reduced protein synthe-
sis, favorable protein processing, and increased folding and 
degradation. However, age-mediated deterioration in these pro-
teostasis network hubs forces the cell to resort to secondary means 
of proteotoxic clearance, which include the ordered assembly of 
toxic oligomers into benign or less-toxic amyloid aggregates. The 
protective aspects of amyloid formation are paradigm shifting and 
have redirected research to identify factors that actively promote 
aggregation and investigate the dynamics between primary and 
secondary detoxification mechanisms.
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